N²-benzoyl-2,6-diaminopyridine | 51505-07-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N²-benzoyl-2,6-diaminopyridine
• 英文别名: N-(6-aminopyridin-2-yl)benzamide；N-(6-amino-pyridin-2-yl)-benzamide；6-Amino-2-benzoylaminopyridin
• CAS: 51505-07-8
• 化学式: C₁₂H₁₁N₃O
• 分子量: 213.239
• InChiKey: BOUHTINVRHZGMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N²-benzoyl-2,6-diaminopyridine 在 吡啶 、 胍 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 168007.33h， 生成 N4-(N6-benzoyl-6-aminopyridin-2-yl)-5'-dimethoxytrityl-2'-deoxycytidine
  参考文献：
  名称：

  The Synthesis ofN⁴-(6-Aminopyridin-2-yl)-2′-deoxycytidine for Recognizing the CG Base Pair at Neutral pH by Oligodeoxyribonucleotide-Directed Triple Helix Formation

  摘要：

  AbstractThe sequence‐specific recognition of double‐helical DNA by oligodeoxyribonucleotide‐directed triple helix (triplex) formation is limited mostly to purine tracts. To interrupt the purine tract in a target sequence, a non‐natural deoxyribonucleoside N4‐(6‐aminopyridin‐2‐yl)‐2′‐deoxycytidine (pC) was designed to interact with the C base in the CG base pair. The protected phosphoramidite synthon of pC was synthesized in seven steps and then was incorporated into an oligodeoxyribonucleotide by an automatic DNA synthesizer. Two 22‐mers, designated as C2 and P, with a common sequence of 5′‐d‐TmCTXTmCTTCTGTCTCCAGACAG were synthesized in this study. mC is 5‐methyl‐2′‐deoxycytidine and X is either 2′‐deoxycytidine (C) or pC for C2 and P, respectively. C2 is able to form a paper clip type triplex with one C · CG mismatched base triad in slightly acidic conditions but not at the neutral pH. On the other hand, P forms a stable triplex under both acidic and neutral conditions. This indicates that pC is able to form a pC · CG base triad in the triplex. Their physical properties were studied by UV thermal melting experiments and circular dichorism spectroscopy (CD). The thermal melting results imply that the pC · CG base triad is as stable as the C+ · GC triad at pH 6.0, and pC helps the triplex formation preferably at neutral to acidic pH. In addition to the hydrogen bonding interaction with the CG base pair, the hydrophobic interaction of pC may also play an important role in stabilizing the triplex formation of oligodeoxyribonucleotides. In the presence of spermine at either pH 5.0 or pH 6.0, the melting temperature of the third strand of P was elevated about 30 and 21 °C, respectively. Thus, spermine can enhance the stability of the triple‐helical structure.

  DOI：

  10.1002/jccs.199900103
• 作为产物：
  描述：

  2,6-二氨基吡啶 、 苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以64.1%的产率得到N²-benzoyl-2,6-diaminopyridine
  参考文献：
  名称：

  [EN] ORGANIC MOLECULES FOR TERAHERTZ TAGGING APPLICATIONS
  [FR] MOLÉCULES ORGANIQUES POUR DES APPLICATIONS DE MARQUAGE PAR TÉRAHERTZ

  摘要：

  本发明公开了含有酰胺和/或脲基并在0.1-10 THz范围内显示共振的取代杂环化合物和/或含有酰胺和/或脲基的芳香化合物。该发明还公开了基于本发明的含有酰胺和/或脲基的取代杂环化合物和/或芳香化合物的二元分子复合物。本发明的化合物和二元分子复合物具有不同的分子质量和氢键强度，展示了10 THz以下的几个共振。本发明的化合物和二元分子复合物可根据不同应用进行定制，例如产品认证。

  公开号：

  WO2015104722A1

文献信息

• [EN] PROTEIN KINASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEUR UTILISATION
  申请人：MERCK SERONO SA

  公开号：WO2009108670A1

  公开（公告）日：2009-09-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  揭示了苯并萘啶衍生物化合物及其类似物，包括含有这些化合物的药物组合物以及制备这些化合物的方法。这些化合物在治疗对激酶信号传导抑制、调节或调控敏感的疾病中很有用。
• POLYMER FILM, RETARDATION FILM, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY, AND COMPOUND
  申请人：FUJIFILM Corporation

  公开号：US20160159750A1

  公开（公告）日：2016-06-09

  Provided is a polymer film containing at least one of a compound represented by formula (1) of hydrates, solvates, or salts thereof. Y is a methine group or nitrogen atom. Q a , Q b , and Q c are a single bond or a divalent linking group. R a , R b , and R c , are hydrogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, cyano group, halogen group, or heterocyclic group. X 2 is a single bond or a divalent linking group. X 1 is a single bond or a predetermined divalent linking group. R 1 and R 2 are a hydrogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, or heterocyclic group Formula (1)

  提供的是一种聚合物薄膜，其中至少包含一种由式（1）表示的化合物的水合物、溶剂合物或盐类。Y是一个亚甲基基团或氮原子。Qa、Qb和Qc是单键或二价连接基团。Ra、Rb和Rc是氢原子、烷基基团、烯基基团、炔基基团、芳基、氰基、卤素基或杂环基。X2是单键或二价连接基团。X1是单键或预定的二价连接基团。R1和R2是氢原子、烷基基团、烯基基团、炔基基团、芳基或杂环基。Formula (1)
• Asymmetric Inverse-Electron-Demand Hetero-Diels-Alder Reaction of Six-membered Cyclic Ketones: An Enamine/Metal Lewis Acid Bifunctional Approach
  作者：Zhenghu Xu、Lu Liu、Kraig Wheeler、Hong Wang

  DOI：10.1002/anie.201100160

  日期：2011.4.4

  On demand: The first example of the title reaction involving cyclic ketones and β,γ‐unsaturated α‐ketoesters has been achieved using the novel enamine/metal Lewis acid bifunctional catalysis (see scheme; Tf=trifluoromethanesulfonyl). Enones with both electron‐withdrawing and electron‐donating groups at the γ position reacted smoothly with cyclohexanone affording the products in excellent chemo‐ and

  随需应变：使用新型烯胺/金属路易斯酸双功能催化（参见方案； Tf =三氟甲磺酰基），实现了涉及环状酮和β，γ-不饱和α-酮酸酯的标题反应的第一个实例。在γ位同时具有吸电子和供电子基团的烯酮与环己酮反应平稳，从而提供具有出色的化学和对映选择性的产物。
• COMPOUNDS EFFECTING GLUCOKINASE
  申请人：BOYD Scott

  公开号：US20090227592A1

  公开（公告）日：2009-09-10

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用式（I）化合物或其盐、溶剂化物或前药，在制备用于治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一种新的式（I）化合物群以及制备式（I）化合物的方法。其中，R1、R2、R3、n和m如规范中所述。
• Compounds Effecting Glucokinase
  申请人：Boyd Scott

  公开号：US20080207636A1

  公开（公告）日：2008-08-28

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用化合物式(I)或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范所述，在制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一类新的化合物式(I)和制备化合物式(I)的方法。